Company profile for BioDelivery Sciences

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies ...
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
4131 ParkLake Avenue, Suite 225 Raleigh, NC 27612
Telephone
Telephone
919 582 9050
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2022/02/24/2391451/0/en/BioDelivery-Sciences-International-Announces-ELYXYB-is-Now-Available-in-the-U-S-for-the-Acute-Treatment-of-Migraine.html

GLOBENEWSWIRE
24 Feb 2022

https://www.contractpharma.com/contents/view_breaking-news/2022-02-14/collegium-purchases-biodelivery-sciences-international-in-all-cash-deal/

J. Carroll CONTRACTPHARMA
15 Feb 2022

https://www.globenewswire.com/news-release/2022/01/20/2370128/0/en/BioDelivery-Sciences-Expects-2021-Revenue-at-the-High-End-of-Full-Year-Guidance.html

GLOBENEWSWIRE
20 Jan 2022

https://www.globenewswire.com/news-release/2021/09/09/2294359/0/en/BioDelivery-Sciences-International-Completes-Acquisition-of-ELYXYB-for-Acute-Migraine-Treatment-in-the-U-S-and-Canada.html

GLOBENEWSWIRE
09 Sep 2021

https://seekingalpha.com/news/3732775-biodelivery-sciences-awarded-24-million-contract-from-dept-of-veteran-affairs

SEEKINGALPFA
20 Aug 2021

https://www.pharmacompass.com/pdf/news/belbuca-buprenorphine-biodelivery-sciences-v-alvogen-pb-rd-1536920931.pdf

PATENT LITIGATION
11 Sep 2018

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty